Innate Pharma (IPHA) Long-Term Investments (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Long-Term Investments data on file, last reported at $12.2 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Investments rose 10.78% year-over-year to $12.2 million; the trailing twelve-month figure through Dec 2025 stood at $12.2 million (up 10.78% YoY), and the FY2025 full-year result was $12.2 million, up 10.78% from the prior year.
• Long-Term Investments for Q4 2025 stood at $12.2 million, up from $11.8 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $48.3 million in Q2 2021 and bottomed at $10.5 million in Q4 2023.
• The 5-year median for Long-Term Investments is $24.0 million (2022), against an average of $26.2 million.
• The widest annual swing landed in 2021, when Long-Term Investments tumbled 99.87%; it then climbed 10.78% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $45.6 million in 2021, then declined by 21.46% to $35.8 million in 2022, then tumbled by 70.58% to $10.5 million in 2023, then gained by 4.23% to $11.0 million in 2024, then increased by 10.78% to $12.2 million in 2025.
• The last three Long-Term Investments figures came in at $12.2 million (Q4 2025), $11.8 million (Q2 2025), and $11.0 million (Q4 2024), per Business Quant data.

Peer Comparison